A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia
Latest Information Update: 18 Feb 2022
At a glance
- Drugs Roflumilast (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Takeda
- 16 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
- 04 May 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov